Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial

SIMPLE SUMMARY: Impaired kidney function is a common complication of a certain blood cancer called multiple myeloma. Patients with severe kidney problems are usually left out of medical studies, so data on safety and efficacy of treatments are limited for these patients. The academic phase II GMMG-D...

Descripción completa

Detalles Bibliográficos
Autores principales: Leypoldt, Lisa B., Gavriatopoulou, Maria, Besemer, Britta, Salwender, Hans, Raab, Marc S., Nogai, Axel, Khandanpour, Cyrus, Runde, Volker, Jauch, Anna, Zago, Manola, Martus, Peter, Goldschmidt, Hartmut, Bokemeyer, Carsten, Dimopoulos, Meletios A., Weisel, Katja C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526417/
https://www.ncbi.nlm.nih.gov/pubmed/37760637
http://dx.doi.org/10.3390/cancers15184667

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526417/
https://www.ncbi.nlm.nih.gov/pubmed/37760637
http://dx.doi.org/10.3390/cancers15184667

Ejemplares similares